このエントリーをはてなブックマークに追加
ID 11642
Eprint ID
11642
フルテキストURL
K003300.pdf 100 KB
タイトル(別表記)
ピルフェニドンは反復抗原暴露により起こる気道過敏性,気道炎症および気道リモデリングを制御する
著者
平野 淳 岡山大学
抄録
We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-beta1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-beta1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling.
キーワード
Mutation
Carcinogenesis
Multivariate analysis
Case-control study
備考
http://dx.doi.org/10.1165/rcmb.2005-0452OC
発行日
2007-03-23
出版物タイトル
資料タイプ
学位論文
学位授与番号
甲第3300号
学位授与年月日
2007-03-23
学位・専攻分野
博士(医学)
授与大学
岡山大学
オフィシャル URL
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16675785&dopt=Abstract
言語
Japanese
論文のバージョン
none
査読
不明